Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection

Boone, Brian A.; Zenati, Mazen S.; Rieser, Caroline; Hamad, Ahmad; Abbas, Amr I. Al; Zureikat, Amer H.; Hogg, Melissa E.; Neal, Matthew D.; Zeh, Herbert J.

doi:10.1245/s10434-018-07148-z

Cited by 23 publications

(49 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past, many prognostic factors have been identified and considered, such as hemoglobin level, tumor burden, liver metastases, venous thromboembolism, baseline expression of B7H1 or B7H4, and baseline CA19-9 [17][18][19][20][21][22][23]. One of the most significant prognostic factors is baseline ECOG PS.…”

Section: Introductionmentioning

confidence: 99%

Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens

et al. 2020

View full text Add to dashboard Cite

Background: Pancreatic cancer has a poor prognosis and few choices of therapy. For patients with adequate performance status, FOLFIRINOX or gemcitabine plus nab-paclitaxel are preferred first-line treatment. 5-Fluorouracil (5-FU)-based therapy (e.g. FOLFIRI, OFF, or FOLFOX) are often used in patients who previously received gemcitabine-based regimens. A systematic review was conducted of the safety and efficacy of FOLFOX for metastatic pancreatic cancer following prior gemcitabine-based therapy. A Bayesian fixed-effect meta-analysis with adjustment of patient performance status (PS) was conducted to evaluate overall survival (OS) and compare outcomes with nanoliposomal irinotecan combination therapy. Methods: PubMed.gov, FDA.gov, ClinicalTrials.gov, congress abstracts, Cochrane.org library, and EMBASE database searches were conducted to identify randomized controlled trials of advanced/metastatic disease, prior gemcitabine-based therapy, and second-line treatment with 5-FU and oxaliplatin. The database search dates were January 1, 1990-June 30, 2019. Endpoints were OS and severe treatment-related adverse events (TRAEs). Trial-level PS scores were standardized by converting Karnofsky grade scores to Eastern Cooperative Oncology Group (ECOG) Grade, and overall study-weighted PS was calculated based on weighted average of all patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Firstly, neutrophils promote release of a variety of inflammatory factors, such as vascular epithelial growth factor, neutrophil elastase, interleukin-8 and matrix metalloproteinase-9, which play important roles in promoting invasion, proliferation, progression and metastasis of cancer cells, and help these cells to escape immune surveillance [ 38 , 39 ]. In addition, platelets promote adhesion of tumor cells to microvascular endothelium and form a defense barrier around circulating tumor cells, helping tumor cells in escaping the immune surveillance of the host [ 40 ]. Moreover, they directly promote tumor growth and metastasis by secreting pro-angiogenic factors and platelet-derived growth factors [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of the systemic immune-inflammation index in pancreatic carcinoma patients: a meta-analysis

Lin

Ouyang

et al. 2021

Bioscience Reports

View full text Add to dashboard Cite

Background: Systemic immune-inflammation index (SII) is a prognostic indicator for several malignancies, including pancreatic carcinoma, however, there is no consensus on its significance. In the current study, a systematic meta-analysis was used to explore the correlation between SII and prognosis in pancreatic carcinoma patients. Methods: PubMed, Embase and Cochrane Library databases were screened from inception to May 2020. Studies describing the prognostic role of SII in pancreatic carcinoma were then retrieved. The pooled hazard ratio (HR) and 95% confidence interval (CI) was calculated using random or fixed effects models to determine the correlation between SII and prognosis. Results: A total of 4 studies, comprising 1,749 patients, met the inclusion criteria of the study and were therefore included in this meta-analysis. The meta-analysis showed that high SII indicated was correlated with worse overall survival in patients with pancreatic carcinoma (HR: 1.43, 95% CI: 1.24-1.65, P < 0.001). These findings were validated through subgroup analyses, stratified by the AJCC stage. In addition, patients with high SII showed poorer cancer-specific survival (HR: 2.32, 95% CI: 1.55-3.48, P < 0.001). However, analysis showed no significant correlations between SII and disease-free and relapse-free survival. Conclusion: These findings indicate that SII is a potential non-invasive and a promising tool for predicting clinical outcomes of pancreatic carcinoma patients. However, the current research did not explore whether neoadjuvant therapy has an effect on the prognostic value of SII. Further studies using adequate designs and larger sample sizes are required to validate these findings.

show abstract

“…Firstly, neutrophils have been proven to promote release of a variety of in ammatory factors, such as vascular epithelial growth factor, neutrophil elastase, interleukin-8, and matrix metalloproteinase-9, which play an important role in promoting the invasion, proliferation, progression, and metastasis of cancer cells, as well as helping these cells to escape immune surveillance [43,44] . In addition, platelets not only promote adhesion of tumor cells to microvascular endothelium, but also form a defense barrier around circulating tumor cells, helping tumor cells escape the host's immune surveillance [45] . Consequently, they directly promote tumor growth and metastasis by secreting pro-angiogenic factors and platelet-derived growth factors [46] .…”

Section: Discussionmentioning

confidence: 99%

Systemic immune‐inflammation index has prognostic significance in pancreatic carcinoma patients: a meta-analysis

Li¹,

Lin²,

Ouyang³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Systemic immune-inflammation index (SII) is reportedly a prognostic indicator for several malignancies, including pancreatic carcinoma, although there exists no consensus regarding its significance. In the current study, we used a systematically meta-analysis to evaluate the association between SII and prognosis in pancreatic carcinoma patients. Methods We screened PubMed, Embase and Cochrane Library databases, through May 2020, and retrieved studies describing the prognostic role of SII in pancreatic carcinoma. We calculated pooled hazard ratio (HR) and 95% confidence interval (CI) using a random or fixed effects models to reveal the correlation between SII and prognosis. Results A total of 4 studies, comprising 1,749 patients, met our inclusion criteria and were therefore eligible for inclusion. Our meta-analysis showed that elevated SII indicated significantly worse overall survival in patients with pancreatic carcinoma (HR: 1.43, 95% CI: 1.24–1.65, P < 0.001), with subgroup analyses, stratified by the TNM stage and treatment, further validating these results. In addition, patients with high SII had poorer cancer-specific survival (HR: 2.32, 95% CI: 1.55–3.48, P < 0.001). However, we found no significant associations between SII with disease-free and relapse-free survival. Conclusions These findings indicate that SII is a potential non-invasive and promising tool for predicting clinical outcomes of pancreatic carcinoma patients. However, further studies using adequate designs and larger sample sizes are required to validate our findings.

show abstract

Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection

Cited by 23 publications

References 20 publications

Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens

Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens

Prognostic significance of the systemic immune-inflammation index in pancreatic carcinoma patients: a meta-analysis

Systemic immune‐inflammation index has prognostic significance in pancreatic carcinoma patients: a meta-analysis

Contact Info

Product

Resources

About